The Panic-Proof Portfolio (Stockchase Research) Haemonetics Corporation HAE-N PAST TOP PICK Nov 09, 2021

Stockchase Research Editor: Michael O'Reilly HAE stock prices took a hit in April when they announced a key client would not be renewing in 2022. The blood and plasma services company provides collection devices, disposables and software solutions. As treatments and collections resume normal activity levels post-pandemic, it is anticipated growth will return to the company. It trades at 28x earnings, compared to peers over 41x. Over 95% of the stock is held by large institutions, allowing for greater staying power. We would purchase this with stop loss at $40, looking to achieve $98 -- upside potential over 70%. Yield 0% (Analysts’ price target is $97.33)

(A Top Pick May 18/21, Up 19.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HAE is progressing well. We now recommend trailing the stop (from $40) to $60. If triggered, this would all but guarantee a marginal return on the original recommended entry.